US Pharma MarketingThe post SpliSense begins Phase IIb SPL84 trial for cystic fibrosis appeared first on Clinical Trials Arena.
SpliSense begins Phase IIb SPL84 trial for cystic fibrosis
SpliSense has commenced a Phase IIb clinical trial of its inhaled antisense oligonucleotide therapy, SPL84, in people with CF. SpliSense anticipates top-line results in the second half of 2027. The ongoing study will recruit around 40 participants. Credit: Gorodenkoff / Shutterstock.com. SpliSense has commenced a Phase IIb clinical trial of its inhaled antisense oligonucleotide therapy, SPL84, in people with cystic fibrosis (CF). SPL84 is intended for individuals with CF carrying the 3849+10 kilobase (Kb) C→T mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. LOA and PTSR Model ELX-02 in Alport Syndrome Reports LOA and PTSR Model -…
SpliSense has commenced a Phase IIb clinical trial of its inhaled antisense oligonucleotide therapy, SPL84, in people with CF.
Source: Clinical Trials Arena